<DOC>
	<DOCNO>NCT00023946</DOCNO>
	<brief_summary>Phase II trial study effectiveness BMS-247550 treating patient liver gallbladder cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Liver Gallbladder Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate patient hepatobiliary cancer treat BMS-247550 . II . Determine toxicity drug patient . III . Determine duration response , median overall survival , time progression patient treat drug . OUTLINE : This multicenter study . Patients receive BMS-247550 IV 3 hour day 1 . Treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Histologically cytologically confirm locally advance , metastatic , recurrent hepatobiliary cancer Liver ( hepatocellular ) Bile duct ( cholangiocarcinoma ) Gallbladder At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan The following consider measurable lesion : Lesions see colonoscopic examination barium study Bone metastases CNS lesion Ascites No brain metastases Performance status ECOG 02 At least 3 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL AST/ALT great 2.5 time upper limit normal Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No grade 2 great peripheral neuropathy No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No prior allergic hypersensitivity reaction attribute compound contain Cremophor EL ( e.g. , paclitaxel compound similar chemical biological composition BMS247550 ) No currently active malignancy except nonmelanoma skin cancer , carcinoma situ cervix , cancer patient complete therapy le 30 % risk relapse Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent immunotherapy No prior chemotherapy No concurrent chemotherapy No concurrent hormonal therapy No concurrent therapeutic radiotherapy At least 30 day since prior investigational agent At least 7 day since prior cimetidine No concurrent cimetidine No concurrent commercial investigational anticancer agent therapies No concurrent unconventional therapy , food , vitamin supplement ( e.g. , St. John 's Wort ) No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>